Lilly’s once‑daily pill posts late‑stage successes. Here’s what the data really say, how it stacks up against rivals, and what to expect on price, coverage, and patient experience.

Novo Nordisk faced critical leadership changes and mounting challenges from Pharmacy Benefit Managers (PBMs) amid fierce competition in the obesity drug market. With a new CEO recently appointed, the company is also doubling down on strategic partnerships in China, aiming to innovate its research pipeline. However, questions remain about the global acceptance of clinical data from these collaborations and the sustainability of Novo’s market position.

The “Research Use Only” Peptide Market Isn’t Slowing Down—It’s Evolving

Novo Nordisk ousted its longtime CEO just two weeks after scoring a major win with CVS Caremark, which named Wegovy its preferred weight-loss drug and dropped Eli Lilly’s Zepbound. But Lilly isn’t flinching. CEO David Ricks dismissed the move as “last decade,” signaling a shift away from exclusive PBM deals and toward direct-to-consumer access. As manufacturers double down on digital pharmacies and price cuts, the real fight for the obesity market may be happening outside the

Caremark, Express Scripts, and OptumRx Face Allegations of Rigging the Rebate System

New Proposal to Expand Medicare Coverage Raises Questions on Cost and Potential Savings

A Heated Exchange on the Super Star Weight Loss Drugs' Price, Big Pharma and PBM's Finger-Pointing Game

Commercial Insurance Dominated Weight Loss Prescriptions, Medicare May Target Wegovy for Price Cuts, FDA Reported Eased Drug Shortages

Soluciones compuestas: abordar la escasez de medicamentos para bajar de peso con precaución y cuidado

Comprensión de los administradores de beneficios de farmacia (PBM): una mirada más cercana a los controvertidos pilares de los costos de los

¿Es la cirugía para bajar de peso la solución definitiva para la obesidad grave?

Ya no es un mito: come menos y muévete más.

¿Cómo mejora el nuevo mandato de la FEHB la cobertura de medicamentos GLP-1 para los empleados federales y sus desafíos?

Equilibrando los crecientes costos y el bienestar de los empleados en la cobertura de medicamentos para bajar de peso

Medicamento para bajar de peso y disfunción eréctil, nueva fábrica de Eli Lilly, recuperación de peso después de dejar de usar el medicament